Is this also not an important part of the report?:
While remestemcel-L and other MSC-based investigational products have demonstrated apparent immunomodulatory effects in in vitro experiments, the ability of remestemcel-L to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated. SR-aGVHD is thought to be an immune-mediated disorder but its etiology is complex and many cell types are likely to be involved in its pathogenesis. Therefore, any efficacy remestemcel-L might have in treating this disease is not sufficient to demonstrate the product’s mechanism of action.
- Forums
- ASX - By Stock
- MSB
- MSB Trading - Aug 2020 on
MSB Trading - Aug 2020 on, page-557
-
- There are more pages in this discussion • 1,828 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
98.0¢ |
Change
-0.015(1.51%) |
Mkt cap ! $1.124B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 98.0¢ | $500.2K | 505.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 26876 | 98.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
98.5¢ | 49052 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 46982 | 0.985 |
11 | 92733 | 0.980 |
8 | 89768 | 0.975 |
16 | 213382 | 0.970 |
7 | 172627 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 28406 | 31 |
0.995 | 85722 | 11 |
1.000 | 81703 | 11 |
1.005 | 32950 | 4 |
1.010 | 39116 | 4 |
Last trade - 11.04am 20/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |